Saniona ABFRA:30S -0.61%67 Current Ratio is 10.55 as of Mar. 2026, which is 156% above its 10-year median of 4.12. GuruFocus rates FRA:30S with a GF Score™ of 67/100 and a GF Value™ of €2.36 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Saniona AB ranks better than 79.6% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Saniona AB's current ratio for the quarter that ended in Mar. 2026 was 10.55.
Saniona AB has a current ratio of 10.55. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Saniona AB's Current Ratio or its related term are showing as below:
FRA:30S'
s Current Ratio Range Over the Past 10 Years
Min: 0.62 Med: 4.12 Max: 13.48
Current: 10.55
During the past 13 years, Saniona AB's highest Current Ratio was 13.48. The lowest was 0.62. And the median was 4.12.
FRA:30S's Current Ratio is ranked better than 79.6% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs FRA:30S: 10.55
Saniona AB (FRA:30S) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Saniona AB Current Ratio Related Terms
Saniona AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Saniona AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:30S vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Saniona AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Saniona AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saniona AB (FRA:30S) has a Current Ratio of 10.55 as of Mar. 2026. This is 156% above median its historical median of 4.12. Over the past decade, Saniona AB's Current Ratio has ranged from 0.62 to 13.48. According to the industry distribution chart, Saniona AB ranks #288 out of 1412 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Saniona AB's Current Ratio too high?
Saniona AB's current Current Ratio of 10.55 is 156% above median its 10-year median of 4.12. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 13.48. The Biotechnology industry median Current Ratio is 3.90. Saniona AB's value of 10.55 is 170.5% above this industry median. Based on the distribution chart, Saniona AB ranks #288 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Saniona AB has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #288 out of 1412 companies for Current Ratio. This places Saniona AB in the top 20% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.90. Saniona AB's value of 10.55 is 170.5% above this benchmark. Historically, Saniona AB's own Current Ratio has ranged from 0.62 to 13.48 over the past decade. While the company's 10-year median is 4.12 vs. the industry median of 3.90, Saniona AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saniona AB's current Current Ratio of 10.55 is 170.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saniona AB's current Current Ratio is 10.55, which is 156% above median its own 10-year median of 4.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (FRA:30S) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.36, compared to a current price of €1.14 — trading 51.9% below its estimated fair value. The current Current Ratio is 10.55, which is 156% above median its 10-year median of 4.12 and 170.5% above the Biotechnology industry median of 3.90. Saniona AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Saniona AB (FRA:30S), the current Current Ratio is 10.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (FRA:30S) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of €1.14 is trading 51.9% below its estimated GF Value™ of €2.36.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for FRA:30S:
Current Ratio: 10.55 (156% above median its 10-year median of 4.12)
GF Value™: €2.36 vs. price of €1.14 (51.9% below fair value)
Industry Position: 170.5% above the Biotechnology median (#288 of 1412)
No single metric tells the full story. See the FRA:30S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
67GF Score
Get the complete analysis for FRA:30S
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:30S has been successfully added to your 
